Synthetic Biologics (NYSE: SYN) announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE